We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $1.65B
1-Year Est. Return 166.99%
This Fund
S&P 500
This Quarter Est. Return
+25.13%
1 Year Est. Return
+166.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
-$469M
Cap. Flow
-$759M
Cap. Flow %
-46.03%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ASMB icon
Assembly Biosciences
ASMB
+$12.8M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$772M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
1
Arcus Biosciences
RCUS
$3.06B
$969M 58.76%
31,424,760
– –
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
$500M 30.34%
16,707,477
– –
ASMB icon
3
Assembly Biosciences
ASMB
$590M
$137M 8.3%
4,977,089
+471,698
+10% +$12.8M
KYTX icon
4
Kyverna Therapeutics
KYTX
$458M
$36.8M 2.23%
4,126,119
– –
XLO icon
5
Xilio Therapeutics
XLO
$58.8M
$6.23M 0.38%
650,389
– –
ACLX
6
DELISTED
Arcellx
ACLX
– –
-6,720,803
Closed -$772M

Similar funds

MCIL
MFF Capital Investments Ltd Sydney $1.65B AUM
OHIF
Oriental Harbor Investment Fund Hong Kong $1.65B AUM 184.75% 1-Year Est. Return
SCM
Shapiro Capital Management Atlanta, Georgia $1.65B AUM 26.74% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.65B AUM 18.1% 1-Year Est. Return
BCM
BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return
SOS
Silver Oak Securities Jackson, Tennessee $1.65B AUM 29.37% 1-Year Est. Return
NPA
Nichols & Pratt Advisers Boston, Massachusetts $1.65B AUM 22.9% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.65B AUM 26.32% 1-Year Est. Return

Gilead Sciences's Q2 2026 Portfolio in Review

As of Q2 2026, Gilead Sciences held 6 positions worth $1.65B, down 22% from $2.12B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Gilead Sciences withdrew a net $759M in Q2 2026, closing 1 position. Its most notable exit was Arcellx, an estimated $772M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Gilead Sciences added an estimated $12.8M to Assembly Biosciences.

  • Gilead Sciences added most to Assembly Biosciences in Q2 2026, an estimated $12.8M increase.
  • Gilead Sciences fully exited Arcellx in Q2 2026, selling an estimated $772M.
  • Gilead Sciences's ten largest holdings make up 100% of its $1.65B portfolio in Q2 2026.
  • Gilead Sciences opened 0 new positions and closed 1 in Q2 2026.
  • Gilead Sciences's portfolio value fell 22% quarter-over-quarter to $1.65B.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.